Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 9/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.37 |
| ▸ | GSK3B | P49841 | 5/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.37 |
| ▸ | CLK3 | P49761 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10285737 | 0.92 | CCNT1 (0.48) | CCNT1CDK9LMNASMN1; SMN2DYRK1A | |
| SCHEMBL10285396 | 0.92 | CCNT1 (0.48) | CCNT1CDK9LMNASMN1; SMN2DYRK1A | |
| SCHEMBL1439813 | 0.90 | CCNT1 (0.60) | CCNT1CDK9 | |
| SCHEMBL1439529 | 0.90 | CCNT1 (0.60) | CCNT1CDK9 | |
| SCHEMBL12814371 | 0.85 | CCNT1 (0.48) | CCNT1CDK9DYRK1AGSK3BCLK2 | |
| SCHEMBL1439570 | 0.84 | CCNT1 (0.54) | CCNT1CDK9DYRK1AGSK3BCLK2 | |
| SCHEMBL10285625 | 0.81 | CCNT1 (0.62) | CCNT1CDK9 | |
| SCHEMBL1439961 | 0.81 | CCNT1 (0.62) | CCNT1CDK9 | |
| SCHEMBL1439593 | 0.81 | CCNT1 (0.62) | CCNT1CDK9 | |
| SCHEMBL1439347 | 0.81 | CCNT1 (0.62) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
| WO-2011026904-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | CCNT1 39/4885CDK9 16/4885LMNA 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.